Cell & Gene: The Podcast
By Erin Harris
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by Erin Harris
Category: Life Sciences
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 12
Reviews: 0
Episodes: 75
Description
Cell & Gene, the most valuable online resource for delivering in-depth content from authoritative authors and sources to professionals in the CGT sector, introduces Cell & Gene: The Podcast. In each episode, Cell & Gene Chief Editor, Erin Harris, will talk to industry and academic leaders about their current initiatives and how they are moving the sector forward.
| Episode | Date |
|---|---|
|
Inside BlueRock Therapeutics' Parkinson's Disease Trial with Dr. Ahmed Enayetallah
|
Apr 25, 2024 |
|
Reducing the Disease Burden of AML with Vor Bio's Dr. Robert Ang
|
Apr 11, 2024 |
|
Reducing Toxicities in Allogeneic Cell Therapies with Orca Bio's Dr. Scott McClellan
|
Mar 28, 2024 |
|
Inside Cellular Rejuvenation Therapies for Age-Related Diseases with Life Biosciences' Sharon Rosenzweig-Lipson, Ph.D.
|
Mar 14, 2024 |
|
The Future of Rare Diseases with The Jackson Laboratory’s Rare Disease Translational Center's Cat Lutz
|
Feb 29, 2024 |
|
Inside Yescarta's Reduced Median Turnaround Time with Kite, a Gilead company's Christopher McDonald
|
Feb 15, 2024 |
|
Pricing, Value, And Access of CGTs With The Dedham Group's Jennifer Klarer, M.Sc.Eng.
|
Feb 01, 2024 |
|
Breaking Down Solid Tumors with Triumvira Immunologics' Dr. Paul Lammers
|
Jan 18, 2024 |
|
4 Keys to Allo in 2024 with Poseida Therapeutics' Kristin Yarema, Ph.D.
|
Jan 04, 2024 |
|
Cell Therapy For Corneal Endothelial Dystrophies With Aurion Biotech's Greg Kunst
|
Dec 21, 2023 |
|
Overcoming the Limitations of CAR T-Cell Therapy with Vittoria Bio's Nick Siciliano, Ph.D.
|
Dec 07, 2023 |
|
Gene Therapy Deals, Collaborations, & Partnerships with Astellas' Richard Wilson
|
Nov 21, 2023 |
|
The Promise of AAV Gene Therapy with REGENXBIO's Ken Mills
|
Nov 09, 2023 |
|
Inside 2023 Meeting on the Mesa with ARM's COO, Rita Johnson-Greene
|
Oct 26, 2023 |
|
The Future of Cell and Organ Transplantation in Treating T1D with Dr. Camillo Ricordi
|
Oct 12, 2023 |
|
In Vivo CAR T-Cell Therapeutics With Umoja Biopharma's Dr. Andrew Scharenberg
|
Sep 28, 2023 |
|
Inside Genome Editing with CBER's Dr. Peter Marks
|
Sep 14, 2023 |
|
The Future of CAR-T with Bristol Myers Squibb's Lynelle Hoch
|
Aug 31, 2023 |
|
The Promise of Genome Editing with Caribou Biosciences' Rachel Haurwitz, Ph.D.
|
Aug 17, 2023 |
|
Focus Areas For Cell Therapy With Bristol Myers Squibb's Stephan Krause, Ph.D.
|
Aug 03, 2023 |
|
The Intersection Of RNA, AI, And Synthetic Biology With Shape Therapeutics' Dr. Francois Vigneault
|
Jul 20, 2023 |
|
Inside Prime Editing with Prime Medicine's Dr. Andrew Anzalone
|
Jul 06, 2023 |
|
Navigating CMC Challenges with Parenteral Drug Association's Glenn Wright
|
Jun 22, 2023 |
|
An Interview with Dr. Usman "Oz" Azam
|
Jun 08, 2023 |
|
Targeting Oncogenic Drivers for Solid Tumor Cancers with Affini-T Therapeutics' Dr. Jak Knowles
|
May 25, 2023 |
|
TJU's Jefferson Institute for Bioprocessing's Impact on CGT with Parviz Shamlou
|
May 11, 2023 |
|
Computational Biology's Role In Gene Therapy With Kriya Therapeutics' Dr. Shankar Ramaswamy
|
Apr 27, 2023 |
|
The Near-Term Future of Exosome Science with Capricor Therapeutics' Dr. Linda Marbán
|
Apr 13, 2023 |
|
Inside the World's First-Ever Allogeneic Approval with Atara Biotherapeutics' Pascal Touchon
|
Mar 30, 2023 |
|
The Potential of RNA Exon Editing with Ascidian Therapeutics' Romesh Subramanian, Ph.D.
|
Mar 16, 2023 |
|
Automating Processes to Scale CGT Manufacturing with PA Consulting's Paolo Siciliano
|
Mar 02, 2023 |
|
The Why Behind In-House Manufacturing With Sangamo's Andy Ramelmeier
|
Feb 16, 2023 |
|
2023 Market Outlook with AdBio and ISCT's Miguel Forte
|
Feb 02, 2023 |
|
CMC and Scale Up with Mustang Bio's Robert Sexton
|
Jan 19, 2023 |
|
An Interview with Dr. Peter Marks
|
Jan 05, 2023 |
|
Inside NK and Macrophage Cellular Immunotherapies with Shoreline Biosciences CSO Dr. Robert Hollingsworth
|
Dec 22, 2022 |
|
The Future of iPSCs with BlueRock Therapeutics' CEO Seth Ettenberg
|
Dec 08, 2022 |
|
Manufacturing at the Point of Care with Orgenesis' CEO Vered Caplan
|
Nov 24, 2022 |
|
Capstan Therapeutics' CEO Laura Shawver on In Vivo Cell Engineering
|
Nov 10, 2022 |
|
PepGen's SVP Head Of Clinical Development On Delivery Of Oligonucleotide Therapies
|
Oct 27, 2022 |
|
BridgeBio's Chief Regulatory Affairs Officer Adora Ndu on PDUFA VII Reauthorization
|
Oct 13, 2022 |
|
Inside RNAi with Arrowhead Pharmaceuticals' Javier San Martin
|
Sep 29, 2022 |
|
Planning For Manufacturing Capacity With Kite Pharma's Will Junker
|
Sep 15, 2022 |
|
Commercialization Learnings with Novartis Gene Therapies' President Chris Fox
|
Sep 01, 2022 |
|
A Stem Cell-Derived Treatment for T1D
|
Aug 18, 2022 |
|
Best Practices for Partnering with a CDMO
|
Aug 04, 2022 |
|
An Interview with Dr. Carl June
|
Jul 21, 2022 |
|
Inside Gamma Delta T Cells with TC BioPharm’s CEO, Bryan Kobel
|
Jul 07, 2022 |
|
Moving On from AAV with Poseida Therapeutics' CEO, Mark Gergen
|
Jun 23, 2022 |
|
Inside the New Hybrid Roles for Cell Therapy Clinical Trials with Immatics' Michael Mehler
|
Jun 09, 2022 |
|
Moving to an Allogeneic RNA Cell Therapy Program with Cartesian Therapeutics' Dr. Metin Kurtoglu
|
May 26, 2022 |
|
Gene Therapy's Commercial Manufacturing Issues with Encoded Therapeutics' Andy Stober
|
May 12, 2022 |
|
Inside CAR-T Therapy For Ovarian Cancer with Anixa Biosciences' Amit Kumar, Ph.D.
|
Apr 28, 2022 |
|
Pivoting to Allogeneic CAR-T Therapies with Celyad Oncology’s CMO, Dr. Charlie Morris
|
Apr 14, 2022 |
|
Rocket Pharmaceuticals' CEO Dr. Gaurav Shah on FDA's Clinical Holds on Gene Therapy Trials
|
Mar 31, 2022 |
|
Inside Solid Tumor Therapies with BlueSphere Bio’s CEO Dr. David Apelian
|
Mar 17, 2022 |
|
Restoration of Immune Balance with Anish Suri, Ph.D., President and CSO at Cue Biopharma
|
Mar 03, 2022 |
|
REGENXBIO's Nina Hunter, Ph.D. Details the Accelerated Approval Pathway for Gene Therapies
|
Feb 17, 2022 |
|
Selecta Biosciences' Dr. Carsten Brunn on Gene Therapy with AAV Vectors
|
Feb 03, 2022 |
|
Cellevolve Bio's Dr. Derrell Porter on the Need for Diversity and Inclusion in Biotech
|
Jan 20, 2022 |
|
RNA's Advantages Over Other Cell Therapies with Cartesian's CSO
|
Jan 06, 2022 |
|
Vor Biopharma's CEO on Genome Engineering of Hematopoietic Stem Cells
|
Dec 22, 2021 |
|
AVROBIO on Patient Advocacy's Role in Clinical Trial Development & Recruitment
|
Dec 09, 2021 |
|
Understanding CAR-M Technology with Carisma Therapeutics' Dr. Debora Barton
|
Nov 24, 2021 |
|
Inside the Gene Therapy for Coronary Artery Disease with XyloCor Therapeutics' Albert Gianchetti
|
Nov 11, 2021 |
|
Advancing Patient Engagement with Novartis Gene Therapies' Dr. Amy Nicole Nayar
|
Oct 28, 2021 |
|
BridgeBio's Approach to Gene Therapy & Nearing the Clinic
|
Oct 14, 2021 |
|
Inside Spark Therapeutics' Investigational SPK-8011 for Hemophilia A
|
Sep 30, 2021 |
|
Gene Therapies for Spinal Cord-Related Disorders with SwanBio's CEO
|
Sep 16, 2021 |
|
Chronic Lymphocytic Leukemia: A Patient's Perspective
|
Sep 02, 2021 |
|
State-of-the-Art GMP Manufacturing RNA Cell Therapies with Cartesian's CEO
|
Aug 19, 2021 |
|
Therapeutic Firsts and "Eds and Meds" with Penn’s Dr. Bruce Levine
|
Aug 05, 2021 |
|
Hospitals And Advanced Therapies with Penn Medicine’s Kevin Mahoney
|
Jul 22, 2021 |
|
Enzyvant's Rachelle Jacques on the Biotech’s Lead Asset
|
Jul 08, 2021 |
|
Introducing Cell & Gene: The Podcast
|
Jun 30, 2021 |